[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 34.238.248.103. Please contact the publisher to request reinstatement.
[Skip to Content Landing]

June 2020 - April 2015

Decade

Year

Issue

July 2020, Vol 6, No. 7, Pages 952-1123

Original Investigation

Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial

Abstract Full Text
open access
JAMA Oncol. 2020;6(7):1003-1010. doi:10.1001/jamaoncol.2020.1024

This randomized clinical trial examines the effect of programmed cell death 1 immune checkpoint inhibition with nivolumab on overall survival for patients with recurrent glioblastoma.

Association of Reduced-Intensity Conditioning Regimens With Overall Survival Among Patients With Non-Hodgkin Lymphoma Undergoing Allogeneic Transplant

Abstract Full Text
JAMA Oncol. 2020;6(7):1011-1018. doi:10.1001/jamaoncol.2020.1278

This cohort study assesses overall survival by comparing 4 reduced-intensity conditioning and nonmyeloablative conditioning regimens in allogeneic hematopoietic cell transplantation treatment for patients with non-Hodgkin lymphoma.

Survival After Minimally Invasive vs Open Radical Hysterectomy for Early-Stage Cervical Cancer: A Systematic Review and Meta-analysis

Abstract Full Text
has active quiz
JAMA Oncol. 2020;6(7):1019-1027. doi:10.1001/jamaoncol.2020.1694

This systematic review and meta-analysis quantifies the risk of recurrence and death associated with minimally invasive vs open radical hysterectomy for early-stage cervical cancer in observational studies optimized to control for confounding.

Evaluation of First-line Radiosurgery vs Whole-Brain Radiotherapy for Small Cell Lung Cancer Brain Metastases: The FIRE-SCLC Cohort Study

Abstract Full Text
has audio
JAMA Oncol. 2020;6(7):1028-1037. doi:10.1001/jamaoncol.2020.1271

This cohort study compares the overall survival, disease progression, and other outcomes of stereotactic radiosurgery with those of whole-brain radiotherapy in patients with brain metastases from small cell lung cancer.

Clarification of Definitions of Hyperprogressive Disease During Immunotherapy for Non–Small Cell Lung Cancer

Abstract Full Text
JAMA Oncol. 2020;6(7):1039-1046. doi:10.1001/jamaoncol.2020.1634

This multicenter cohort study assesses the accuracy of each definition of hyperprogressive disease to identify the frequency and associations with poorer outcomes of immune-checkpoint inhibitor therapy in patients with advanced non–small cell lung cancer and offers an optimized and homogenized definition based on all previous criteria for identifying hyperprogressive disease.

Effect of Osimertinib and Bevacizumab on Progression-Free Survival for Patients With Metastatic EGFR-Mutant Lung Cancers: A Phase 1/2 Single-Group Open-Label Trial

Abstract Full Text
JAMA Oncol. 2020;6(7):1048-1054. doi:10.1001/jamaoncol.2020.1260

This interventional clinical trial examines the safety and tolerability of osimertinib and bevacizumab combination treatment and assesses the 12-month progression-free survival of the combination in patients with metastatic EGFR-mutant lung cancers.

Association of Mental Health Treatment With Outcomes for US Veterans Diagnosed With Non–Small Cell Lung Cancer

Abstract Full Text
JAMA Oncol. 2020;6(7):1055-1062. doi:10.1001/jamaoncol.2020.1466

This cohort study evaluates the association of participation in mental health treatment, housing support, or employment support programs with stage at diagnosis, receipt of stage-appropriate treatment, and mortality among US veterans with a preexisting mental health disorder and a diagnosis of non–small cell lung cancer.

Effect of Delayed Targeted Intraoperative Radiotherapy vs Whole-Breast Radiotherapy on Local Recurrence and Survival: Long-term Results From the TARGIT-A Randomized Clinical Trial in Early Breast Cancer

Abstract Full Text
open access online only
JAMA Oncol. 2020;6(7):e200249. doi:10.1001/jamaoncol.2020.0249

This secondary analysis of the TARGIT-A randomized clinical trial compares the effect of delayed second-procedure targeted intraoperative radiotherapy (TARGIT-IORT) with whole-breast external beam radiotherapy (ERBT) on local recurrence at 5 years and long-term survival outcomes among women with early breast cancer.

Low-Dose Erlotinib Treatment in Elderly or Frail Patients With EGFR Mutation–Positive Non–Small Cell Lung Cancer: A Multicenter Phase 2 Trial

Abstract Full Text
online only
JAMA Oncol. 2020;6(7):e201250. doi:10.1001/jamaoncol.2020.1250

This single-arm, multicenter phase 2 trial investigates the efficacy and safety of low-dose erlotinib in elderly or frail patients with EGFR mutation–positive non–small cell lung cancer.

Brief Report

Assessment of the Feasibility and Safety of Durvalumab for Treatment of Solid Tumors in Patients With HIV-1 Infection: The Phase 2 DURVAST Study

Abstract Full Text
JAMA Oncol. 2020;6(7):1063-1067. doi:10.1001/jamaoncol.2020.0465

This nonrandomized phase 2 study assesses the feasibility and safety of durvalumab treatment in adults with advanced solid tumors and HIV-1 infection.

Outcomes Following Immune Checkpoint Inhibitor Treatment of Patients With Microsatellite Instability-High Cancers: A Systematic Review and Meta-analysis

Abstract Full Text
JAMA Oncol. 2020;6(7):1068-1071. doi:10.1001/jamaoncol.2020.1046

This systematic review and meta-analysis evaluates the association of immune checkpoint inhibitor treatment with overall response rate, disease control rate, overall survival, and progression-free survival in patients with microsatellite instability-high cancers.

Research Letter

Incidence of Opioid-Associated Deaths in Cancer Survivors in the United States, 2006-2016: A Population Study of the Opioid Epidemic

Abstract Full Text
JAMA Oncol. 2020;6(7):1100-1102. doi:10.1001/jamaoncol.2020.0799

This study analyzes the incidence of opioid-associated deaths in cancer survivors vs the general population in the US from 2006 through 2016 using National Center for Health Statistics death certificate data.

Association of Mandatory-Access Prescription Drug Monitoring Programs With Opioid Prescriptions Among Medicare Patients Treated by a Medical or Hematologic Oncologist

Abstract Full Text
JAMA Oncol. 2020;6(7):1102-1103. doi:10.1001/jamaoncol.2020.0804

This cohort study examines the association between prescription drug monitoring program mandates with and without a cancer exemption and the percent of oncologists’ patients with any opioid prescription covered by Medicare Part D.

Association of Behavioral Nudges With High-Value Evidence-Based Prescribing in Oncology

Abstract Full Text
JAMA Oncol. 2020;6(7):1104-1106. doi:10.1001/jamaoncol.2020.0746

This interrupted time series analysis evaluates the association of nudges with zoledronate prescription vs more expensive denosumab.

Trends in Provision of Palliative Radiotherapy and Chemotherapy Among Hospices in the United States, 2011-2018

Abstract Full Text
JAMA Oncol. 2020;6(7):1106-1108. doi:10.1001/jamaoncol.2020.0923

This case series study uses Medicare 2011-2019 Hospice Cost Report Data to analyze trends in the proportion of freestanding hospices in the United States providing radiotherapy and chemotherapy, as well as the expenses incurred for providing these therapies.

SARS-CoV-2 Transmission in Patients With Cancer at a Tertiary Care Hospital in Wuhan, China

Abstract Full Text
open access has active quiz
JAMA Oncol. 2020;6(7):1108-1110. doi:10.1001/jamaoncol.2020.0980

This cross-sectional study reviews the medical records of 1524 patients with cancer treated at a single tertiary care hospital in Wuhan, China, to evaluate the characteristics associated with transmission of the SARS-CoV-2 virus.

Minimally Invasive Surgery and Risk of Capsule Rupture for Women With Early-Stage Ovarian Cancer

Abstract Full Text
JAMA Oncol. 2020;6(7):1110-1113. doi:10.1001/jamaoncol.2020.1702

This cohort study examines the association between the use of minimally invasive surgery, capsule rupture, and survival among women with stage I epithelial ovarian cancer.

Review

Assessment of Therapy-Related Myeloid Neoplasms in Patients With Neuroendocrine Tumors After Peptide Receptor Radionuclide Therapy: A Systematic Review

Abstract Full Text
JAMA Oncol. 2020;6(7):1086-1092. doi:10.1001/jamaoncol.2020.0078

This systematic review evaluates the literature and reports the incidence, time of diagnosis, and nature of therapy-related myeloid neoplasms after peptide receptor radionuclide therapy.

JAMA Oncology Clinical Challenge

Brain Lesion in the Setting of Chronic Rituximab Treatment

Abstract Full Text
has active quiz
JAMA Oncol. 2020;6(7):1093-1094. doi:10.1001/jamaoncol.2020.0160

A 75-year old woman with a history of follicular lymphoma and breast cancer presents with gradual vision loss and confusion; magnetic resonance imaging reveals hyperintensity in the left occipital and temporal lobes. What is your diagnosis?

Viewpoint

Shared and Usable Data From Phase 1 Oncology Trials—An Unmet Need

Abstract Full Text
JAMA Oncol. 2020;6(7):980-981. doi:10.1001/jamaoncol.2020.0144

This Viewpoint describes the importance of sharing data from completed trials to strengthen and guide further research.

Hippocampal-Sparing Radiotherapy for Patients With Glioblastoma and Grade II-III Gliomas

Abstract Full Text
JAMA Oncol. 2020;6(7):981-983. doi:10.1001/jamaoncol.2020.0164

This Viewpoint advocates for the consideration of hippocampal-sparing radiotherapy in patients with gliomas to mitigate treatment-related adverse events.

How (or Do) People “Think” About Cancer Risk, and Why That Matters

Abstract Full Text
JAMA Oncol. 2020;6(7):983-984. doi:10.1001/jamaoncol.2020.0170

This Viewpoint highlights the importance of understanding the sources and variations in people’s notions of cancer risk.

Editorial

Results From the CheckMate 143 Clinical Trial: Stalemate or New Game Strategy for Glioblastoma Immunotherapy?

Abstract Full Text
JAMA Oncol. 2020;6(7):987-989. doi:10.1001/jamaoncol.2020.0857

Registry Data and Conditioning Therapy for Allogeneic Hematopoietic Cell Transplant and Lymphoma

Abstract Full Text
JAMA Oncol. 2020;6(7):989-991. doi:10.1001/jamaoncol.2020.1303

Minimally Invasive Surgery for Gynecologic Cancers—A Cautionary Tale

Abstract Full Text
JAMA Oncol. 2020;6(7):991-993. doi:10.1001/jamaoncol.2020.1617
Invited Commentary

Radiosurgery in Patients With Small Cell Lung Cancer With Brain Metastases: A Call for Prospective Evidence

Abstract Full Text
JAMA Oncol. 2020;6(7):1037-1038. doi:10.1001/jamaoncol.2020.1245

Hyperprogressive Disease After Treatment With Checkpoint Inhibitors: Time for Prospective Studies

Abstract Full Text
JAMA Oncol. 2020;6(7):1046-1047. doi:10.1001/jamaoncol.2020.1633

Managing Cancer Pain During the Opioid Epidemic—Balancing Caution and Compassion

Abstract Full Text
JAMA Oncol. 2020;6(7):1103-1104. doi:10.1001/jamaoncol.2020.0779
Cancer Care Chronicles

Facing a Pandemic While Pregnant

Abstract Full Text
free access has active quiz
JAMA Oncol. 2020;6(7):985-986. doi:10.1001/jamaoncol.2020.1652

In this essay, the author describes her experience being pregnant during the coronavirus disease 2019 pandemic.

Comment & Response

Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer

Abstract Full Text
JAMA Oncol. 2020;6(7):1113-1114. doi:10.1001/jamaoncol.2020.0625

Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer

Abstract Full Text
JAMA Oncol. 2020;6(7):1114-1115. doi:10.1001/jamaoncol.2020.0628

Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer

Abstract Full Text
JAMA Oncol. 2020;6(7):1115. doi:10.1001/jamaoncol.2020.0631

Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer

Abstract Full Text
JAMA Oncol. 2020;6(7):1115-1116. doi:10.1001/jamaoncol.2020.0637

Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer—Reply

Abstract Full Text
JAMA Oncol. 2020;6(7):1116-1117. doi:10.1001/jamaoncol.2020.0646

De-Escalating Breast Cancer Surgery for Low-Risk Ductal Carcinoma in Situ

Abstract Full Text
JAMA Oncol. 2020;6(7):1117-1118. doi:10.1001/jamaoncol.2020.0816

De-Escalating Breast Cancer Surgery for Low-Risk Ductal Carcinoma in Situ—Reply

Abstract Full Text
JAMA Oncol. 2020;6(7):1118. doi:10.1001/jamaoncol.2020.0819

Shortlist of Quality Indicators for End-of-Life Cancer Care

Abstract Full Text
JAMA Oncol. 2020;6(7):1118-1119. doi:10.1001/jamaoncol.2020.1159

Shortlist of Quality Indicators for End-of-Life Cancer Care—Reply

Abstract Full Text
JAMA Oncol. 2020;6(7):1119-1120. doi:10.1001/jamaoncol.2020.1162

Value of Oncology Pharmacists in the Oncology Health Care Workforce

Abstract Full Text
JAMA Oncol. 2020;6(7):1120-1121. doi:10.1001/jamaoncol.2020.1288

Value of Oncology Pharmacists in the Oncology Health Care Workforce—Reply

Abstract Full Text
JAMA Oncol. 2020;6(7):1121. doi:10.1001/jamaoncol.2020.1291

Analysis of Overall Survival Benefit of Abemaciclib Plus Fulvestrant in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer

Abstract Full Text
JAMA Oncol. 2020;6(7):1121-1122. doi:10.1001/jamaoncol.2020.1513

Analysis of Overall Survival Benefit of Abemaciclib Plus Fulvestrant in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer

Abstract Full Text
JAMA Oncol. 2020;6(7):1122. doi:10.1001/jamaoncol.2020.1516

Analysis of Overall Survival Benefit of Abemaciclib Plus Fulvestrant in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer—Reply

Abstract Full Text
JAMA Oncol. 2020;6(7):1122-1123. doi:10.1001/jamaoncol.2020.1518
Correction

Change in License Type and Error in Figure 1

Abstract Full Text
free access
JAMA Oncol. 2020;6(7):1123. doi:10.1001/jamaoncol.2020.1749
JAMA Oncology Masthead

JAMA Oncology

Abstract Full Text
free access
JAMA Oncol. 2020;6(7):952. doi:10.1001/jamaoncol.2019.4233
×